ADVERTISEMENT

Conference Report

ESMO 2022 – Neoadjuvant immunotherapy for colon cancer

Cristina Ferrario — Agenzia Zoe   |   12 September 2022

Takeaway

  • 4 weeks of neoadjuvant immunotherapy led to major pathologic response (10% or less residual viable tumour) in 95% of patients with locally advanced mismatch repair-deficient (dMMR) colon cancer, including 67% pathologic complete response ( no residual viable tumour in both the primary tumour bed and lymph nodes ).
  • Neoadjuvant immunotherapy...

          

November Challenge

Ends in 1d 6h
left
right

Topic Challenges

left
right